SANA Stock Price, Sana Biotechnology, Inc. Quote, Chart

Market Summary

USD8.27-0.14

Market Closed

-1.66%

SANA Alerts

1 major insider sales recently.

SANA Stock Price

View Fullscreen

SANA RSI Chart

SANA Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-6.44

Price/Free Cashflow

-6.66

SANA Price/Earnings (Trailing)

SANA Profitability

Return on Equity

-98.52%

Return on Assets

-50.11%

Free Cashflow Yield

-15.01%

SANA Fundamentals

SANA Earnings

Earnings (TTM)

-283.3M

Earnings Growth (Yr)

-9.54%

Earnings Growth (Qtr)

-9.1K%

Breaking Down SANA Revenue

Last 7 days

-8.1%

Last 30 days

-7.2%

Last 90 days

46.4%

Trailing 12 Months

49.0%

How does SANA drawdown profile look like?

SANA Financial Health

Current Ratio

3.31

SANA Investor Care

Shares Dilution (1Y)

3.36%

Diluted EPS (TTM)

-1.47

Tracking the Latest Insider Buys and Sells of Sana Biotechnology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	bishop hans edgar	acquired	-	-	2,774	-
Mar 08, 2024	yang patrick y	sold	-236,300	9.452	-25,000	-
Feb 08, 2024	arch venture fund x, l.p.	bought	6,000,000	5.5	1,090,910	-
Feb 08, 2024	nelsen robert	bought	6,000,000	5.5	1,090,910	-
Feb 08, 2024	crandell keith	bought	6,000,000	5.5	1,090,910	-
Jan 05, 2024	bishop hans edgar	acquired	-	-	4,901	-
Jan 05, 2024	wilderotter mary agnes	acquired	-	-	1,470	-
Dec 15, 2023	hordo christian	sold	-300,098	4.0013	-75,000	evp, chief business officer
Oct 05, 2023	wilderotter mary agnes	acquired	-	-	2,077	-
Oct 05, 2023	bishop hans edgar	acquired	-	-	6,925	-

Which funds bought or sold SANA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Arlington Trust Co LLC	unchanged	-	2,155	3,640	-%
Apr 16, 2024	Viewpoint Capital Management LLC	unchanged	-	139,386	235,450	0.15%
Apr 12, 2024	NORTHWEST INVESTMENT COUNSELORS, LLC	new	-	7,500	7,500	-%
Apr 05, 2024	CWM, LLC	new	-	1,000	1,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	reduced	-47.83	153,127	702,450	-%
Apr 05, 2024	GAMMA Investing LLC	added	107	1,347	1,830	-%
Mar 11, 2024	VANGUARD GROUP INC	added	6.87	4,493,550	39,972,100	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	170	4,396,520	6,775,180	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	2.47	14,471	194,592	-%
Feb 26, 2024	Virtu Financial LLC	added	59.63	31,000	76,000	0.01%

Are Funds Buying or Selling SANA?

Are funds buying SANA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SANA

No. of Funds

SANA Alerts

1 major insider sales recently.

Unveiling Sana Biotechnology, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	fmr llc	-	0	SC 13G/A
Mar 07, 2024	baillie gifford & co	4.70%	10,360,620	SC 13G/A
Feb 14, 2024	flagship ventures fund v, l.p.	0.5%	1,035,208	SC 13G/A
Feb 09, 2024	arch venture fund ix, l.p.	22.3%	44,042,500	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	baillie gifford & co	5.15%	10,150,017	SC 13G/A
Apr 26, 2023	fmr llc	-	0	SC 13G
Feb 13, 2023	arch venture fund ix, l.p.	23.1%	44,042,500	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jan 20, 2023	baillie gifford & co	5.64%	10,764,727	SC 13G/A

Recent SEC filings of Sana Biotechnology, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	3	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 03, 2024	SC 13G/A	Major Ownership Report
Mar 11, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Sana Biotechnology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Sana Biotechnology, Inc. News

Latest updates

Sana Biotechnology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-10.5%	565	631	707	747	823	898	971	1,048	1,129	1,233	1,260	1,304	730
Current Assets	-23.6%	214	280	339	370	444	500	494	523	558	613	860	967	384
Cash Equivalents	-20.7%	134	168	174	160	177	174	205	197	253	442	677	753	127
Net PPE	3.4%	71.00	68.00	63.00	64.00	67.00	67.00	68.00	69.00	65.00	63.00	59.00	51.00	47.00
Goodwill	0%	141	141	141	141	141	141	141	141	141	141	141	141	141
Liabilities	4.6%	278	266	352	319	323	332	332	346	401	403	354	422	299
Current Liabilities	-3.2%	64.00	67.00	112	103	112	115	97.00	94.00	99.00	92.00	43.00	35.00	31.00
Shareholder's Equity	-21.4%	288	366	355	428	499	566	640	702	729	830	906	882	-421
Retained Earnings	-4.0%	-1,300	-1,249	-1,300	-1,100	-1,054	-974	-889	-816	-785	-674	-591	-610	-429
Additional Paid-In Capital	0.6%	1,626	1,616	1,607	1,567	1,558	1,547	1,535	1,524	1,515	1,505	1,497	1,492	8.00
Shares Outstanding	0.4%	198	197	197	191	191	188	188	186	166	161	180	119	-
Float	-	-	-	600	-	-	-	1,200	-	-	-	3,700	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	18.2%	-51,959	-63,550	-58,801	-79,272	-76,067	-64,796	-71,478	-77,709	-110,099	-50,486	-40,556	-49,913	-37,559	-37,510	-33,366	-29,547	-
Share Based Compensation	-11.9%	7,931	9,003	9,848	8,751	10,591	10,080	9,911	7,755	7,313	5,950	4,941	4,158	2,791	1,166	1,116	755	-
Cashflow From Investing	-70.2%	15,310	51,348	42,627	62,727	88,428	31,859	77,730	12,545	-73,661	-185,904	-35,324	49,091	13,041	-268,313	-36,472	39,181	-
Cashflow From Financing	818.7%	1,718	187	29,505	236	1,061	1,621	1,579	652	3,119	1,596	333	626,703	103	4.00	435,578	2.00	-

SANA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 268,823	$ 285,885	$ 248,626
Research and development related success payments and contingent consideration	(48,981)	(84,882)	57,873
General and administrative	73,299	71,561	50,410
Total operating expenses	293,141	272,564	356,909
Loss from operations	(293,141)	(272,564)	(356,909)
Interest income, net	9,938	3,762	676
Other income (expense), net	(52)	(674)	305
Net loss	$ (283,255)	$ (269,476)	$ (355,928)
Net loss per common share - basic	$ (1.46)	$ (1.43)	$ (2.14)
Net loss per common share - diluted	$ (1.46)	$ (1.43)	$ (2.14)
Weighted-average number of common shares - basic	194,541	188,344	166,433
Weighted-average number of common shares - diluted	194,541	188,344	166,433

SANA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 133,517	$ 176,765
Marketable securities	71,678	247,198
Restricted cash	3,832	6,100
Prepaid expenses and other current assets	4,488	14,374
Total current assets	213,515	444,437
Long-term marketable securities		10,051
Property and equipment, net	70,689	66,917
Operating lease right-of-use assets	74,903	92,486
Long-term restricted cash		4,408
Intangible asset	59,195	59,195
Goodwill	140,627	140,627
Other non-current assets	6,370	4,599
TOTAL ASSETS	565,299	822,720
Current liabilities:
Accounts payable	4,108	2,857
Accrued compensation	23,722	26,362
Accrued expenses and other current liabilities	23,462	14,547
Operating lease liabilities	13,195	12,393
Contingent consideration		55,345
Total current liabilities	64,487	111,504
Operating lease liabilities, net of current portion	90,901	95,860
Contingent consideration, net of current portion	109,606	95,034
Success payment liabilities	12,799	21,007
Total liabilities	277,793	323,405
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value; 750,000 shares authorized; 197,857 and 191,022 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	20	19
Additional paid-in capital	1,625,637	1,558,459
Accumulated other comprehensive loss	(60)	(4,327)
Accumulated deficit	(1,338,091)	(1,054,836)
Total stockholders' equity	287,506	499,315
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 565,299	$ 822,720

About Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.

CEO	Dr. Steven D. Harr M.D.
WEBSITE	sana.com
INDUSTRY	Biotechnology
EMPLOYEES	424

Sana Biotechnology, Inc. Frequently Asked Questions

What is the ticker symbol for Sana Biotechnology, Inc.? What does SANA stand for in stocks?

SANA is the stock ticker symbol of Sana Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sana Biotechnology, Inc. (SANA)?

As of Wed Apr 17 2024, market cap of Sana Biotechnology, Inc. is 1.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SANA stock?

You can check SANA's fair value in chart for subscribers.

What is the fair value of SANA stock?

You can check SANA's fair value in chart for subscribers. The fair value of Sana Biotechnology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sana Biotechnology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SANA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sana Biotechnology, Inc. a good stock to buy?

The fair value guage provides a quick view whether SANA is over valued or under valued. Whether Sana Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact Sana Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SANA.